pyrazines has been researched along with Neuroendocrine Tumors in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bendell, J; de Haan, H; Filvaroff, EH; Hege, K; Li, S; Mahipal, A; Meyer, T; Mita, A; Mita, M; Munster, PN; Nemunaitis, J; Paz-Ares, L; Wolin, E | 1 |
| Anthony, LB; Carreira, VS; Chu, Z; Dahche, HM; Jiang, M; Koch, SE; Komurov, K; LaSance, K; Mercer, CA; Orr-Asman, MA; Plas, DR; Qi, X; Rubinstein, J; Thomas, HE; Worley, M | 1 |
| Atkinson, M; Butler, AE; Butler, PC; Campbell-Thompson, M; Dawson, DW; Gurlo, T | 1 |
| François, RA; Hochwald, SN; Kaye, FJ; Maeng, K; Nawab, A; Zajac-Kaye, M | 1 |
| Granberg, D; Hassan, S; Larsson, DE; Oberg, K; Wickström, M | 1 |
| Grever, M; Kindler, HL; Kleiber, B; Shah, MH; Webb, I; Wright, J; Young, D | 1 |
2 trial(s) available for pyrazines and Neuroendocrine Tumors
| Article | Year |
|---|---|
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.
Topics: Administration, Oral; Adult; Aged; Carcinoid Tumor; Cohort Studies; Female; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Middle Aged; Neuroendocrine Tumors; Pyrazines | 2019 |
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoid Tumor; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome | 2004 |
4 other study(ies) available for pyrazines and Neuroendocrine Tumors
| Article | Year |
|---|---|
mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment.
Topics: Animals; Carcinoid Heart Disease; Cell Line, Tumor; Drug Resistance, Neoplasm; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Mice; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazines; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.
Topics: Adenoma; Adolescent; Adult; Aged; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hyperplasia; Incretins; Insulin-Secreting Cells; Male; Middle Aged; Neuroendocrine Tumors; Organ Size; Pancreas; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Focal Adhesion Kinase 1; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neuroendocrine Tumors; Organic Chemicals; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro.
Topics: Apoptosis; Benzophenanthridines; Boronic Acids; Bortezomib; Brefeldin A; Carcinoid Tumor; Carcinoma, Bronchogenic; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Lung Neoplasms; Naphthoquinones; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrazines | 2010 |